WO2005035570A3 - Variants of cd40l protein - Google Patents

Variants of cd40l protein Download PDF

Info

Publication number
WO2005035570A3
WO2005035570A3 PCT/US2004/033707 US2004033707W WO2005035570A3 WO 2005035570 A3 WO2005035570 A3 WO 2005035570A3 US 2004033707 W US2004033707 W US 2004033707W WO 2005035570 A3 WO2005035570 A3 WO 2005035570A3
Authority
WO
WIPO (PCT)
Prior art keywords
variants
cd40l
present
cd40l protein
agonists
Prior art date
Application number
PCT/US2004/033707
Other languages
French (fr)
Other versions
WO2005035570A2 (en
Inventor
Aaron Keith Chamberlain
John R Desjarlais
Gregory L Moore
Original Assignee
Xencor Inc
Aaron Keith Chamberlain
John R Desjarlais
Gregory L Moore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xencor Inc, Aaron Keith Chamberlain, John R Desjarlais, Gregory L Moore filed Critical Xencor Inc
Priority to EP04794935A priority Critical patent/EP1673389A2/en
Publication of WO2005035570A2 publication Critical patent/WO2005035570A2/en
Publication of WO2005035570A3 publication Critical patent/WO2005035570A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154

Abstract

The present invention relates to soluble, recombinant CD40L variant proteins that may be expressed solubly in E. coli. The variants of the present invention may substantially reduced binding to alpha IIb-beta3 integrin, act as CD40L antagonists or agonists, and methods for generating the same.
PCT/US2004/033707 2003-10-10 2004-10-12 Variants of cd40l protein WO2005035570A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP04794935A EP1673389A2 (en) 2003-10-10 2004-10-12 Novel variants of cd40l protein

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US51043003P 2003-10-10 2003-10-10
US60/510,430 2003-10-10
US51772803P 2003-11-05 2003-11-05
US60/517,728 2003-11-05
US52354503P 2003-11-20 2003-11-20
US60/523,545 2003-11-20

Publications (2)

Publication Number Publication Date
WO2005035570A2 WO2005035570A2 (en) 2005-04-21
WO2005035570A3 true WO2005035570A3 (en) 2005-11-03

Family

ID=34437673

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/033707 WO2005035570A2 (en) 2003-10-10 2004-10-12 Variants of cd40l protein

Country Status (2)

Country Link
EP (1) EP1673389A2 (en)
WO (1) WO2005035570A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7381792B2 (en) 2002-01-04 2008-06-03 Xencor, Inc. Variants of RANKL protein
US7399829B2 (en) 2002-01-04 2008-07-15 Xencor, Inc. Variants of RANKL protein
US7553930B2 (en) 2003-01-06 2009-06-30 Xencor, Inc. BAFF variants and methods thereof
WO2005113598A2 (en) * 2004-05-21 2005-12-01 Xencor, Inc. Tnf super family members with altered immunogenicity
WO2007054658A1 (en) * 2005-11-14 2007-05-18 King's College London Control of immune responses
DK2066339T3 (en) 2006-09-18 2014-11-03 Univ Arkansas Compositions and Methods for Boosting Immune Reactions
WO2008061377A1 (en) * 2006-11-22 2008-05-29 Centre Hospitalier De L'universite De Montreal Novel receptor for cd40l and uses thereof
AU2008318615A1 (en) 2007-10-30 2009-05-07 Texas A&M University System Compositions and methods of enhancing immune responses to flagellated bacterium
DK3097926T3 (en) 2007-11-01 2019-12-16 Univ Arkansas Compositions and Methods for Boosting Immune Reactions on Eimeria
EP2310405A4 (en) 2008-07-11 2011-08-10 Phylogica Ltd Peptide inhibitors of cd40l signaling and uses therefor
EA023058B1 (en) 2010-01-21 2016-04-29 Дзе Борд Оф Трастиз Оф Дзе Юниверсити Оф Арканзас Vaccine vectors and methods of enhancing immune responses
CA2800830C (en) 2010-06-09 2020-09-08 The Board Of Trustees Of The University Of Arkansas Vaccine and methods to reduce campylobacter infection
PT2956165T (en) 2013-02-14 2019-11-29 Texas A & M Univ Sys Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection
US10376571B2 (en) 2013-03-15 2019-08-13 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to enteric pathogens
KR20190015712A (en) 2016-05-03 2019-02-14 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 Yeast vaccine vectors comprising immunostimulatory and antigenic polypeptides, and methods of using the same
EP4302768A3 (en) 2017-06-22 2024-05-01 Board Of Regents, The University Of Texas System Methods for producing regulatory immune cells and uses thereof
JP2021513860A (en) 2018-02-21 2021-06-03 ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System Universal antigen presenting cells and their use
KR20210152536A (en) * 2019-04-12 2021-12-15 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 Methods for producing regulatory B cells and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040918A2 (en) * 1995-06-07 1996-12-19 Immunex Corporation Novel cd40l mutein
WO2002018445A2 (en) * 2000-09-01 2002-03-07 Biogen, Inc. Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design
WO2002087627A1 (en) * 2001-04-27 2002-11-07 Xcyte Therapies, Inc. Maturation of antigen-presenting cells using activated t cells

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040918A2 (en) * 1995-06-07 1996-12-19 Immunex Corporation Novel cd40l mutein
WO2002018445A2 (en) * 2000-09-01 2002-03-07 Biogen, Inc. Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design
WO2002087627A1 (en) * 2001-04-27 2002-11-07 Xcyte Therapies, Inc. Maturation of antigen-presenting cells using activated t cells

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
BAJORATH J ET AL: "ANALYSIS OF GP39/CD40 INTERACTIONS USING MOLECULAR MODELS AND SITE-DIRECTED MUTAGENESIS", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, PA, US, vol. 34, no. 31, 8 August 1995 (1995-08-08), pages 9884 - 9892, XP002017168, ISSN: 0006-2960 *
DATABASE Geneseq [online] 19 September 1997 (1997-09-19), "Human CD40L mutein C194K.", XP002320694, retrieved from EBI accession no. GSN:AAW09116 Database accession no. AAW09116 *
DATABASE Geneseq [online] 28 June 2002 (2002-06-28), "Human CD145 mutant, S128R/E129G.", XP002320695, retrieved from EBI accession no. GSN:AAM49210 Database accession no. AAM49210 *
GARBER ELLEN ET AL: "CD154 variants associated with hyper-IgM syndrome can form oligomers and trigger CD40-mediated signals", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 274, no. 47, 19 November 1999 (1999-11-19), pages 33545 - 33550, XP002189390, ISSN: 0021-9258 *
MILTON HARRIS J ET AL: "EFFECT OF PEGYLATION ON PHARMACEUTICALS", NATURE REVIEWS. DRUG DISCOVERY, NATURE PUBLISHING GROUP, BASINGSTOKE, GB, vol. 2, no. 3, March 2003 (2003-03-01), pages 214 - 221, XP009042217, ISSN: 1474-1784 *
NONOYAMA SHIGEAKI ET AL: "Mutations of the CD40 ligand gene in 13 Japanese patients with X-linked hyper-IgM syndrome", HUMAN GENETICS, vol. 99, no. 5, 1997, pages 624 - 627, XP002320659, ISSN: 0340-6717 *
PRASAD K S SRINIVASA ET AL: "Soluble CD40 ligand induces beta3 integrin tyrosine phosphorylation and triggers platelet activation by outside-in signaling.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 100, no. 21, 14 October 2003 (2003-10-14), pages 12367 - 12371, XP002320662, ISSN: 0027-8424 *
SEYAMA KUNIAKI ET AL: "Mutations of the CD40 ligand gene and its effect on CD40 ligand expression in patients with X-linked hyper IgM syndrome", BLOOD, vol. 92, no. 7, 1 October 1998 (1998-10-01), pages 2421 - 2434, XP002320660, ISSN: 0006-4971 *
SINGH JUSWINDER ET AL: "The role of polar interactions in the molecular recognition of CD40L with its receptor CD40", PROTEIN SCIENCE, vol. 7, no. 5, May 1998 (1998-05-01), pages 1124 - 1135, XP002320661, ISSN: 0961-8368 *
VERONESE F M: "Peptide and protein PEGylation - a review of problems and solutions", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 22, no. 5, 1 March 2001 (2001-03-01), pages 405 - 417, XP004227886, ISSN: 0142-9612 *

Also Published As

Publication number Publication date
EP1673389A2 (en) 2006-06-28
WO2005035570A2 (en) 2005-04-21

Similar Documents

Publication Publication Date Title
WO2005035570A3 (en) Variants of cd40l protein
AU2003228809A1 (en) Kinase anchor protein muteins, peptides thereof, and related methods
WO2005067601A3 (en) Vectors for recombinant protein expression in e.coli
WO2005046709A3 (en) Tgf - beta binding and supported peptides
WO2005118620A3 (en) Methods for preparing internally constraied peptides and peptidomimetics
WO2007081419A3 (en) Compositions and methods related to anti-fgf agents
WO2006074390A3 (en) Methods of treating obesity with combination therapeautics of igf-i fusion polypeptides
WO2005021592A3 (en) Enhancing the circulating half-life of interleukin-2 proteins
WO2004081028A3 (en) Allergen peptide fragments and use thereof
EP2399936A3 (en) Anti-CD154 antibodies
WO2007035716A3 (en) Compositions comprising receptor-associated protein (rap) variants specific for cr-containing proteins and uses thereof
WO2006138343A3 (en) Compositions comprising receptor - associated protein (rap) variants specific for lrp2 and uses thereof
WO2006023356A3 (en) Selective vpac2 receptor peptide agonists
IL173952A0 (en) Anti-angiogenic peptides and pharmaceutical compositions based thereon
WO2006060680A3 (en) Mda-7 protein variants having antiproliferative activity
AU2002217010A1 (en) Peptides, the production and use thereof for binding immunoglobulins
IL172729A0 (en) Reagents and methods for the formation of disulfide bonds and the glycosylation of proteins
WO2005028497A3 (en) Receptor binding peptides derived from the sars s protein
WO2005072766A3 (en) Peptides that bind to hsp90 proteins
WO2006049983A3 (en) Peptide yy modified transferrin fusion proteins
WO2003059281A3 (en) Novel variants of rankl protein
WO2006103354A3 (en) Dermatological and/or cosmetic composition containing proteins of the sirt family
MXPA04002103A (en) A caspase- 8 binding protein, its preparation and use.
WO2005004894A3 (en) Methods for increasing cell and tissue viability
WO2003057708A3 (en) Fusion proteins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004794935

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004794935

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2004794935

Country of ref document: EP